Cargando…

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain

OBJECTIVES: To investigate the use of once-weekly semaglutide in a real population of people with type 2 diabetes mellitus (T2DM) in three Spanish hospitals. METHOD: An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing b...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia de Lucas, Maria Dolores, Miramontes-González, Jose Pablo, Avilés-Bueno, Beatriz, Jiménez-Millán, Ana Isabel, Rivas-Ruiz, Francisco, Pérez-Belmonte, Luis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523693/
https://www.ncbi.nlm.nih.gov/pubmed/36187123
http://dx.doi.org/10.3389/fendo.2022.995646
_version_ 1784800344157454336
author Garcia de Lucas, Maria Dolores
Miramontes-González, Jose Pablo
Avilés-Bueno, Beatriz
Jiménez-Millán, Ana Isabel
Rivas-Ruiz, Francisco
Pérez-Belmonte, Luis M.
author_facet Garcia de Lucas, Maria Dolores
Miramontes-González, Jose Pablo
Avilés-Bueno, Beatriz
Jiménez-Millán, Ana Isabel
Rivas-Ruiz, Francisco
Pérez-Belmonte, Luis M.
author_sort Garcia de Lucas, Maria Dolores
collection PubMed
description OBJECTIVES: To investigate the use of once-weekly semaglutide in a real population of people with type 2 diabetes mellitus (T2DM) in three Spanish hospitals. METHOD: An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting. The primary endpoint was the change in HbA1c from baseline to the end of the study. The secondary endpoints included changes in body weight and the proportion of people with T2DM, achieving HbA1c <7.0% and body weight loss >5%. RESULTS: After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p<0.001) in the total cohort, -1.13 ± 1.38% (p<0.019) for GLP-1RA-naïve participants, and -0.74 ± 0.9% (p<0.023) for GLP-1RA-experienced participants. Body weight reductions were -12.42 ± 9.1% in GLP-1RA-naïve participants vs. -7.65 ± 9.7% in GLP-1RA-experienced participants (p<0.001). In the total cohort, 77.1% reached the objective of an HbA1c level <7%, and 12.7% reached between 7.1% and 7.5%. Additionally, 66.9% achieved a weight reduction ≥5%. Of all cohort, 90% received 1 mg of semaglutide once a week. The reported adverse events were consistent with the known safety profile of semaglutide. CONCLUSIONS: In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM, without notable adverse effects, which supports real-world use.
format Online
Article
Text
id pubmed-9523693
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95236932022-10-01 Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain Garcia de Lucas, Maria Dolores Miramontes-González, Jose Pablo Avilés-Bueno, Beatriz Jiménez-Millán, Ana Isabel Rivas-Ruiz, Francisco Pérez-Belmonte, Luis M. Front Endocrinol (Lausanne) Endocrinology OBJECTIVES: To investigate the use of once-weekly semaglutide in a real population of people with type 2 diabetes mellitus (T2DM) in three Spanish hospitals. METHOD: An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting. The primary endpoint was the change in HbA1c from baseline to the end of the study. The secondary endpoints included changes in body weight and the proportion of people with T2DM, achieving HbA1c <7.0% and body weight loss >5%. RESULTS: After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p<0.001) in the total cohort, -1.13 ± 1.38% (p<0.019) for GLP-1RA-naïve participants, and -0.74 ± 0.9% (p<0.023) for GLP-1RA-experienced participants. Body weight reductions were -12.42 ± 9.1% in GLP-1RA-naïve participants vs. -7.65 ± 9.7% in GLP-1RA-experienced participants (p<0.001). In the total cohort, 77.1% reached the objective of an HbA1c level <7%, and 12.7% reached between 7.1% and 7.5%. Additionally, 66.9% achieved a weight reduction ≥5%. Of all cohort, 90% received 1 mg of semaglutide once a week. The reported adverse events were consistent with the known safety profile of semaglutide. CONCLUSIONS: In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM, without notable adverse effects, which supports real-world use. Frontiers Media S.A. 2022-09-16 /pmc/articles/PMC9523693/ /pubmed/36187123 http://dx.doi.org/10.3389/fendo.2022.995646 Text en Copyright © 2022 Garcia de Lucas, Miramontes-González, Avilés-Bueno, Jiménez-Millán, Rivas-Ruiz and Pérez-Belmonte https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Garcia de Lucas, Maria Dolores
Miramontes-González, Jose Pablo
Avilés-Bueno, Beatriz
Jiménez-Millán, Ana Isabel
Rivas-Ruiz, Francisco
Pérez-Belmonte, Luis M.
Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
title Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
title_full Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
title_fullStr Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
title_full_unstemmed Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
title_short Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
title_sort real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in spain
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523693/
https://www.ncbi.nlm.nih.gov/pubmed/36187123
http://dx.doi.org/10.3389/fendo.2022.995646
work_keys_str_mv AT garciadelucasmariadolores realworlduseofonceweeklysemaglutideinpatientswithtype2diabetesatanoutpatientclinicinspain
AT miramontesgonzalezjosepablo realworlduseofonceweeklysemaglutideinpatientswithtype2diabetesatanoutpatientclinicinspain
AT avilesbuenobeatriz realworlduseofonceweeklysemaglutideinpatientswithtype2diabetesatanoutpatientclinicinspain
AT jimenezmillananaisabel realworlduseofonceweeklysemaglutideinpatientswithtype2diabetesatanoutpatientclinicinspain
AT rivasruizfrancisco realworlduseofonceweeklysemaglutideinpatientswithtype2diabetesatanoutpatientclinicinspain
AT perezbelmonteluism realworlduseofonceweeklysemaglutideinpatientswithtype2diabetesatanoutpatientclinicinspain